The expansion, which includes the addition of multiple holding rooms, and dedicated procedure and formulation spaces, more than triples CrownBio’s capacity at the site.
The USDA-certified facilities are also fitted with Biosafety Level 2 environmental controls and are able to handle viral agents for oncolytic virus studies.
According to the company, the expansion enables scientists to isolate and compartmentalize incoming projects, and includes separate suites infectious agents.
The addition also grows CrownBio’s immuno-oncology capabilities, with separate rooms dedicated to immunocompetent and immunodeficient models.
As Outsourcing-Pharma.com previously reported, the company recently expanded its immune-oncology offerings at its facilities in Europe, the US, and Asia to include immunophenotyping analysis.
The expanded offerings include a collection of validated models and services for in vivo pharmacodynamic and efficacy studies.
The additions come in response to a growing demand for immuno-oncology offerings – a market which is expected to see annual revenues of up to $40bn by 2020.